Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Triple-negative breast cancer

    - PMLiVE

    Merck announces agreement with US government to reduce prices of prescription medication

    The pharma company will invest more than $70bn in the US to boost production and innovation

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

    Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

    Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

    Weinreich brings clinical development and venture capital experience to the role

    - PMLiVE

    Eli Lilly’s Inluriyo approved by FDA for breast cancer

    The oral drug can be used to treat advanced or metastatic breast cancer

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links